公开(公告)号：US20200038374A1

公开(公告)日：2020-02-06

申请号：US16653297

申请日：2019-10-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Tasir Shamsul Haque ,  Louis J. Lombardo ,  John E. Macor ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar ,  Trevor C. Sherwood ,  Shoshana L. Posy ,  Ramesh Kumar Sistla ,  Subramanya Hegde ,  Anupama Kandhi Ramachandra Reddy

IPC: A61K31/4196 ,  C07D249/00 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US10544143B2

公开(公告)日：2020-01-28

申请号：US16222145

申请日：2018-12-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  Sreekantha Ratna Kumar

IPC: C07D519/00 ,  A61K31/437 ,  C07D471/04 ,  C07D491/107 ,  C07D471/08 ,  A61P25/00 ,  A61P29/00 ,  A61P19/02 ,  C07D495/10

Abstract: Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US10544133B2

公开(公告)日：2020-01-28

申请号：US16009389

申请日：2018-06-15

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Rajeev S. Bhide ,  John V. Duncia ,  John Hynes ,  Satheesh Kesavan Nair ,  William J. Pitts ,  Sreekantha Ratna Kumar ,  Daniel S. Gardner ,  Natesan Murugesan ,  Venkatram Reddy Paidi ,  Joseph B. Santella ,  Ramesh Kumar Sistla ,  Hong Wu

IPC: C07D407/14 ,  C07D401/14 ,  C07D401/12 ,  C07D417/14 ,  C07D213/74 ,  C07D405/12 ,  C07D405/14

Abstract: Compounds having the following formula: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.

公开(公告)号：US10478424B2

公开(公告)日：2019-11-19

申请号：US16042116

申请日：2018-07-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Alaric J. Dyckman ,  Dharmpal S. Dodd ,  Christopher P. Mussari ,  Laxman Pasunoori ,  Sreekantha Ratna Kumar

IPC: A61K31/4196 ,  A61K31/437 ,  A61K31/4427 ,  A61K45/06 ,  C07D249/00 ,  C07D471/04

Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

公开(公告)号：US20190292191A1

公开(公告)日：2019-09-26

申请号：US16314574

申请日：2016-06-23

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： John V. Duncia ,  Daniel S. Gardner ,  John Hynes ,  John E. Macor ,  Natesan Murugesan ,  Joseph B. Santella ,  Hong Wu ,  Durgarao Kantheti ,  Satheesh Kesavan Nair ,  Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Kandhasamy Sarkunam ,  Ramesh Kumar Sistla ,  Subba Rao Polimera

IPC: C07D487/04 ,  C07D471/04 ,  C07D413/04 ,  C07D401/14

Abstract: Disclosed are compounds of Formula (I) Formula (I) or salts thereof, wherein HET is a heteroaryl selected from oxazolyl, pyrazolyl, imidazo[1,2-b]pyridazin-3-yl, and pyrazolo[1,5-a]pyrimidin-3-yl, wherein said heteroaryl is attached to the pyridinyl group in the compound of Formula (I) by a carbon ring atom in the heteroaryl and wherein said heteroaryl is substituted with zero to 2 Rb; and R1, R3, and Rb are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.

公开(公告)号：US09862715B2

公开(公告)日：2018-01-09

申请号：US14960785

申请日：2015-12-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Sistla ,  Satheesh Kesavan Nair ,  William J. Pitts ,  John Hynes

IPC: C07D417/04 ,  C07D417/14 ,  C07D413/14 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds having the following formula: or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.

公开(公告)号：US09242976B2

公开(公告)日：2016-01-26

申请号：US14371463

申请日：2013-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Sistla ,  Satheesh Kesavan Nair ,  William J. Pitts ,  John Hynes

IPC: C07D417/14 ,  C07D413/14 ,  C07D413/04 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.

Abstract translation: 具有下式（I）的化合物或其对映体，非对映异构体或其药学上可接受的盐，其中X为N或C-R7，可用作激酶调节剂，包括IRAK-4调节。

公开(公告)号：US20150018344A1

公开(公告)日：2015-01-15

申请号：US14371463

申请日：2013-01-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Venkatram Reddy Paidi ,  Sreekantha Ratna Kumar ,  Abhisek Banerjee ,  Ramesh Sistla ,  Satheesh Kesavan Nair ,  William J. Pitts ,  John Hynes

IPC: C07D417/14 ,  C07D417/04

CPC classification number: C07D417/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D487/04

Abstract: Compounds having the following formula (I) or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.

Abstract translation: 具有下式（I）的化合物或其对映体，非对映异构体或其药学上可接受的盐，其中X为N或C-R7，可用作激酶调节剂，包括IRAK-4调节。